Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. As an avid Pilates goer, I appreciated this story.
Viking Therapeutics said this morning that in a Phase 2 trial, its injectable obesity candidate, initially tested as a weekly treatment, still looked to be efficacious after transitioning to every-other-week or monthly dosing.
To read the rest of this story subscribe to STAT+.
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Originally reported by STAT News.